HIV patients get continued access to key drug in safety study
NCT ID NCT00980538
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This study gives HIV-1 patients ongoing access to the drug etravirine until they can switch to a local treatment option. It includes 180 participants aged 2 and older who previously benefited from etravirine in a parent trial. The main goal is to monitor safety by tracking any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Los Angeles, California, United States
-
Study site
Washington D.C., District of Columbia, United States
-
Study site
New York, New York, United States
-
Study site
Philadelphia, Pennsylvania, United States
-
Study site
Buenos Aires, Argentina
-
Study site
Ciudad Autonoma de Buenos Aire, Argentina
-
Study site
Belo Horizonte, Brazil
-
Study site
Ribeirão Preto, Brazil
-
Study site
Rio de Janeiro, Brazil
-
Study site
Montreal, Quebec, Canada
-
Study site
Lyon, France
-
Study site
Paris, France
-
Study site
Panama City, Panama
-
Study site
Rio Piedras, Puerto Rico
-
Study site
Bucharest, Romania
-
Study site
Bloemfontein, South Africa
-
Study site
Boksburg, South Africa
-
Study site
Cape Town, South Africa
-
Study site
Dundee, South Africa
-
Study site
Durban, South Africa
-
Study site
George, South Africa
-
Study site
Johannesburg, South Africa
-
Study site
Newtown, South Africa
-
Study site
Pretoria, South Africa
-
Study site
Esplugues de Llobregat, Spain
-
Study site
Madrid, Spain
-
Study site
Seville, Spain
-
Study site
Bangkok, Thailand
-
Study site
Khon Kaen, Thailand
Conditions
Explore the condition pages connected to this study.